Showing 1 - 4 results of 4 for search 'A.S. Bjartell', query time: 0.02s Refine Results
  1. 1
    Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts

    Combination of the PARP inhibitor olaparib with the vascular disrupting agent NOV202 reduces tumor growth in BRCA1/2 mutated prostate cancer xenografts by A.S. Bjartell, E. Sereti, S. Evans Axelsson

    Published 2023-02-01
    Get full text
    Article
  2. 2
    Towards organised prostate cancer testing in Sweden

    Towards organised prostate cancer testing in Sweden by A.S. Bjartell, M. Alterbeck, E. Thimansson, J. Bengtsson, E. Baubeta Frid, S. Zackrisson, M. Mansoori, T. Jiborn

    Published 2022-08-01
    Get full text
    Article
  3. 3
    Residual/recurrent disease and deaths at 6 years after open or robotic-assisted radical prostatectomy in the prospective, controlled trial LAPPRO

    Residual/recurrent disease and deaths at 6 years after open or robotic-assisted radical prostatectomy in the prospective, controlled trial LAPPRO by M.P. Nyberg, O. Akre, D. Bock, S.V. Carlsson, S. Carlsson, J. Hugosson, G. Steineck, J. Stranne, S. Tyritzis, P. Wiklund, E. Haglind, A.S. Bjartell

    Published 2020-07-01
    Get full text
    Article
  4. 4
    Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized disease (D0) at diagnosis

    Apalutamide (APA) for metastatic castration-sensitive prostate cancer (mCSPC) in TITAN: Outcomes in patients (pts) with de novo (D1) mCSPC vs. progression to mCSPC after localized... by A.S. Bjartell, D. Ye, N. Agarwal, B.H. Chung, R. Given, A. Merseburger, M. Özgüroğlu, A. Juárez Soto, H. Uemura, A. Lopez-Gitlitz, G. Li, S. Mc Carthy, K.N. Chi, S. Chowdhury

    Published 2020-07-01
    Get full text
    Article

Search Tools: